Five new projects are to be funded under the Genome Canada and Social Science and Humanities Research Council (SSHRC) Joint Initiative on Societal Implications of Genomics Research. These projects explore the significant ethical, economic, environmental, legal and/or social challenges and opportunities engendered by the new wave of innovations in genomics, covering topics such as genetically modified foods and synthetic biology.
Have a great genomics solution for climate change focused on mitigation of emissions? Ontario’s Low Carbon Innovation Fund (LCIF) supports proof-of-concept, prototyping and pilot demonstration projects aiming to reduce Greenhouse Gas (GHG) emissions. The LCIF is accepting Eligibility Assessments until Dec 10th for its Technology Validation Stream supporting proof-of-concept and prototyping.
New technologies are sexy if they meet three criteria: they open doors to new and wonderful things, they are disruptive, and they are profitable. Genomics has proven its worth in the dairy industry, helping to triple milk production. But the beef industry may not be ready to follow suit. Here’s why.
Government of Canada and partners invest more than $24 million in genomics research projects to improve cancer treatments and reduce greenhouse gas emissions.
BGI and Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, awarded investment from Genome Canada and Ontario Genomics PRESS RELEASE – Shenzhen, China and Toronto, Canada, November 30, 2017 ‒ BGI and the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health System, today announced the signing of a Memorandum of Understanding (MOU) outlining their intention to…
Doctors in Europe used gene therapy to grow sheets of health skin that saved the life of a boy with a rare genetic disease that had destroyed most of his skin.
New research from Australia has shown that the combined affected pregnancy rate of cystic fibrosis, fragile X syndrome and spinal muscular atrophy is comparable to the population risk for Down syndrome. This highlights the need to offer carrier screening routinely, not just to those individuals with a family history.
Ontario Genomics has closed an investment in Rapid Novor, a Kitchener-Waterloo based biotech company that provides rapid, accurate, de novo protein sequencing services across Canada and internationally. This was another investment from the 2017 round of the Pre-commercial Business Development Fund (PBDF), which supports commercially promising ‘omics technologies. To date, Rapid Novor has offered monoclonal…
The appeal of precision medicine is the promise that we can understand disease with greater specificity and fashion treatments that are more individualized and more effective. A core tenet is that diseases such as type 2 diabetes may be a compilation of many subgroups, and that we can develop distinct treatments for each. But, at least outside of oncology, could there be an alternate tenet?
MIT scientists have engineered a new molecular system for efficiently editing RNA in human cells. Unlike the permanent changes to the genome required for DNA editing with CRISPR/Cas9, RNA editing is a potentially reversible way to make corrections in the cell, for instance as a treatment for rare diseases.